Abstract: The present invention relates to a composition comprising Lactobacillus crispatus LB714R, deposited under the accession number DSM 33732, Lactobacillus gasseri LB905R deposited under accession number DSM 34094, Lactobacillus crispatus LB912R deposited under accession number DSM 34095, Lactobacillus jensenii LB918R deposited under accession number DSM 34096, or Lactobacillus crispatus LB919R deposited under accession number DSM 34097.

Abstract: The present invention relates to a composition comprising Pediococcus pentosaceus LB606R, deposited under the assession number DSM 33730; Lactiplantibacillus plantarum, LB679R, deposited under the assession number DSM 33731; or a combination hereof.

Abstract: The present invention relates to a composition for improvement of a skin condition comprising a supernatant produced from fermentation of a bacteria wherein the supernatant comprises at least 3 metabolites produced by the bacteria during fermentation wherein the at least 3 metabolites include at least one of succinic acid, 2-Hydroxyisocaproic acid, azelaic acid and/or salicylic acid, 5 and wherein at least one of succinic acid, 2-Hydroxyisocaproic acid, azelaic acid, and/or salicylic acid is/are produced by fermentation of a lactic acid bacteria.

Abstract: The present invention relates to a composition for control of microbial development of an edible substance the composition comprises a supernatant comprising a bacteriocin produced from fermentation of a bacteriocin producing bacteria and an organic acid produced from fermentation of a bacteriocin producing bacteria, wherein organoleptic characteristics of the edible substance are not significantly altered.

Abstract: The present invention relates to methods for treatment or prevention of asthma, mild intermittent asthma, mild persistent asthma, moderate persistent asthma, severe persistent asthma, eosinophilic asthma, neutrophilic asthma, steroid refractory asthma, status asthmaticus, pneumonia, bronchiectasis, COPD, sarcoidosis, and lung cancer based on reducing airway hyper responsiveness, increasing pulmonary compliance, reducing lung inflammation, reducing inflammatory cell count in bronchoalveolar fluid and reducing cytokine production by administration of a mammalian ?- and/or ?-defensin.

Abstract: The present invention relates to methods for treatment or prevention of asthma, mild intermittent asthma, mild persistent asthma, moderate persistent asthma, severe persistent asthma, eosinophilic asthma, neutrophilic asthma, steroid refractory asthma, status asthmaticus, pneumonia, bronchiectasis, COPD, sarcoidosis, and lung cancer based on reducing airway hyper responsiveness, increasing pulmonary compliance, reducing lung inflammation, reducing inflammatory cell count in bronchoalveolar fluid and reducing cytokine production by administration of a mammalian ?- and/or ?-defensin.

Abstract: The present invention relates to microbial lysozyme, compositions comprising such and uses thereof.

Abstract: A composition comprises: (i) at least one fermented seaweed material; (ii) at least one fermented plant material: or (iii) a combination of at least one fermented seaweed material and at least one fermented plant material; and at least one lactic acid bacterial strain, for treating, alleviating, suppressing and/or preventing growth of a resistant organism.

Abstract: The present invention relates to a microcapsule comprising a fat-based coating surrounding a composition providing an encapsulated composition, the encapsulated composition comprising a viable microorganism, and a water content below 5% (w/w).

Abstract: The present invention relates to a composition comprising at least one lactic acid bacterium for use in decreasing the transfer of a pathogenic microorganism between a surface of a first subject and a surface of a second subject.

Abstract: A process controlling development of at least two predetermined metabolites in a fermented product comprising at least one plant material and/or at least one seaweed material, the process comprising the steps of: (i) Determining the at least 2 predetermined metabolites to be developed in the fermented product; (ii) Based on the predetermined metabolites determined in step (i) selecting at least one plant material and/or the at least one seaweed material; (iii) Based on the predetermined metabolites determined in step (i) selecting at least one fermenting organism; (iv) Mixing the at least one plant material and/or the at least one seaweed material selected in step (ii) with the at least one fermenting organism selected in step (iii) in a fermentation reactor providing a fermentation mixture; (v) Allowing the fermentation mixture to ferment under fermentation conditions favoring development of the at least two predetermined metabolites; whereby the fermented product is provided.

Abstract: The present invention relates to microbial lysozyme, compositions comprising such and uses thereof.

Abstract: An animal feed product comprising a basic feed compound and a fermented ingredient, wherein the fermented ingredient comprising one or more health-enhancing microorganism and at least one fermented seaweed material; at least one fermented plant material; or a combination of at least one fermented seaweed material and at least one fermented plant material; and wherein the animal feed product comprises a reduced content or no medicinal zinc (Zn) and the fermented ingredient is a dried fermented ingredient, and wherein a range of 20-80% (w/w) of the dry fermented ingredient has a particle size below 0.5 mm (preferably in the range of 0.01-0.5 mm), and wherein 20-80% (w/w) of the dry fermented ingredient comprises a particle size above 0.5 mm (preferably in the range of 0.5-1.0 mm).

Abstract: An anti-parasitic composition is provided that includes at least one seaweed material, at least one plant material, or a combination of at least one seaweed material and at least one plant material, for inhibiting, reducing, and/or suppressing growth of at least one parasite.

Abstract: The present invention relates to a human food comprising a basic food product and an ingredient, wherein the ingredient comprising one or more health-enhancing microorganism and a combination of at least one fermented seaweed material and at least one fermented plant material.

Abstract: The current invention relates to the task of masking, i.e. determination of boundaries in an image of biological particles and/or elements or parts of biological particles in image cytometry. Methods for masking of a biological particle or element or region of a biological particle in a sample are provided which include staining a first element or region of the biological particle with a first fluorescent dye, staining a second element or region of the biological particle with a second fluorescent dye, recording an image of the fluorescent light signal emitted from the sample, and determining boundaries of the biological particle or element or region of the biological particle based on the fluorescent light signal in the image.

Abstract: The present invention relates to methods and systems for image cytometry analysis, typically at low optical magnification, where analysis is based on detection of biological particles using UV bright field and optionally one or more sources of excitation light.

Abstract: The present invention relates to methods and systems for image cytometry analysis, in particular using light sources to be cooled. Thereby is provided optimal light conditions for image cytometry.

Abstract: The current invention relates to the task of masking, i.e. determination of boundaries in an image of biological particles and/or elements or parts of biological particles in image cytometry.

Abstract: The present invention relates to microbial lysozyme, compositions comprising such and uses thereof.